Dealbreaker on MSN2h
Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH TumultAltitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...
Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...
Recent internal guidance restricting the National Institutes of Health’s spending could affect researchers across the country, including those at Binghamton University. On Jan. 22, ...
Earlier this month, the Trump administration directed the National Institutes of Health (NIH) to impose limits on specific ...
The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...
Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs impacted by the uncertainty surrounding federal grants.
Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.
If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...
The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.
Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback